UNCYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Unicycive Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$3.51+0.15 (+4.46%)
Close on Oct 19, 2026
- Market cap
- $94.48M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
46.9%
13M of 28M shares
Institutional holders
80
36 new, 7 sold out
Net institutional buying
3M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Ms. Lillian Nordahl | 796,558 | 6.24% | 13G (passive) amendment | Jun 30, 2025 |
| Vivo Opportunity Fund Holdings, L.P. | 60,961,729 | 9.99% | 13G (passive) amendment | Mar 31, 2025 |
| Vivo Opportunity, LLC | 4,856,259 | 9.99% | 13G (passive) amendment | Jun 30, 2026 |
| Daniel Mack | 2,807,830 | 9.99% | 13G (passive) amendment | Jun 30, 2026 |
| Peter Kolchinsky | 2,801,082 | 9.90% | 13G (passive) amendment | Mar 31, 2026 |
| Rajeev Shah | 1,960,230 | 9.90% | 13G (passive) amendment | Sep 30, 2025 |
| Nantahala Capital Management, LLC | 1,855,991 | 9.99% | 13G (passive) amendment | Sep 30, 2025 |
| Lampert Mark N | 1,417,117 | 9.99% | 13G (passive) amendment | Jun 30, 2025 |
| BlackRock, Inc. | 1,413,381 | 5.30% | 13G (passive) | Jun 30, 2026 |
| Integrated Core Strategies (US) LLC | 1,172,667 | 5.50% | 13G (passive) | Jan 16, 2026 |
| Great Point Partners, LLC | 11,473,166 | 9.99% | 13G (passive) amendment | Dec 31, 2024 |
| Wilmot B. Harkey | 10,879,142 | 9.99% | 13G (passive) amendment | Dec 19, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of UNCY | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Nantahala Capital Management, LLC | 2,802,894 | 10.06% | $13.15M | +1,863,692 | 0.22% |
| BlackRock, Inc. | 1,413,381 | 5.07% | $6.63M | +1,377,478 | 0.00% |
| Vanguard Capital Management LLC | 1,071,481 | 3.85% | $5.03M | +260,051 | 0.00% |
| Octagon Capital Advisors LP | 1,000,000 | 3.59% | $4.69M | – | 0.42% |
| Geode Capital Management, LLC | 564,019 | 2.02% | $2.65M | +360,275 | 0.00% |
| Vivo Capital, LLC | 550,000 | 1.97% | $2.58M | −1,239,916 | 0.24% |
| Marshall Wace, Llp | 547,862 | 1.97% | $2.57M | +392,924 | 0.00% |
| Logos Global Management LP | 473,563 | 1.70% | $2.22M | – | 0.10% |
| State Street Corp | 450,162 | 1.62% | $2.11M | +370,135 | 0.00% |
| Diametric Capital, LP | 374,132 | 1.34% | $1.75M | +293,770 | 0.19% |
| J. Goldman & Co LP | 327,345 | 1.18% | $1.54M | New | 0.04% |
| Diadema Partners LP | 303,676 | 1.09% | $1.42M | +197,593 | 0.18% |
| Millennium Management LLC | 271,456 | 0.97% | $1.27M | −1,127,892 | 0.00% |
| Dauntless Investment Group, LLC | 214,000 | 0.77% | $1.00M | +66,913 | 0.79% |
| Citigroup Inc | 182,654 | 0.66% | $856.65K | +182,653 | 0.00% |
| Northern Trust Corp | 181,930 | 0.65% | $853.25K | +145,993 | 0.00% |
| Vanguard Portfolio Management LLC | 169,196 | 0.61% | $793.53K | New | 0.00% |
| Susquehanna International Group, Llp | 160,039 | 0.57% | $750.58K | −39,180 | 0.00% |
| Jump Financial, LLC | 153,000 | 0.55% | $717.57K | New | 0.01% |
| Vanguard Fiduciary Trust Co | 148,965 | 0.53% | $698.65K | +47,891 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 80 | 13M | 46.9% | 36 / 23 | 11 / 7 | 7M | 4M |
| Q1 2026 | 51 | 10M | 35.6% | 20 / 10 | 11 / 3 | 3M | 0M |
| Q4 2025 | 35 | 8M | 29.6% | 8 / 8 | 6 / 2 | 2M | 0M |
| Q3 2025 | 30 | 6M | 22.6% | 13 / 9 | 1 / 3 | 1M | 0M |
| Q2 2025 | 20 | 5M | 18.5% | 20 / 0 | 0 / 0 | 5M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of UNCY | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 805,716 | 2.89% | $3.78M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 616,216 | 2.21% | $2.89M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 268,848 | 0.97% | $1.35M | 0.00% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 240,017 | 0.86% | $1.13M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 201,744 | 0.72% | $946.18K | 0.01% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 84,554 | 0.30% | $624.01K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 81,976 | 0.29% | $384.47K | 0.03% | Jun 30, 2026 |
| Dimensional U.S. Small Cap ETF | 67,827 | 0.24% | $339.81K | 0.00% | Jul 31, 2026 |
| Schwab Small-Cap Index Fund | 54,842 | 0.20% | $274.76K | 0.00% | Jul 31, 2026 |
| Master Small Cap Index Series | 45,675 | 0.16% | $214.22K | 0.00% | Jun 30, 2026 |
| Nuveen Small Cap Blend Index Fund | 33,059 | 0.12% | $165.63K | 0.00% | Jul 31, 2026 |
| Fidelity Total Market Index Fund | 26,975 | 0.10% | $199.08K | 0.00% | May 31, 2026 |
| EQ/2000 Managed Volatility Portfolio | 26,528 | 0.10% | $124.42K | 0.00% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 24,577 | 0.09% | $181.38K | 0.00% | May 31, 2026 |
| iShares Russell 2000 Value ETF | 23,641 | 0.08% | $110.88K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Shalabh K. Gupta | CEO, Director | 5,973,471 | 21.44% | Jun 15, 2026 |
| John Townsend | CFO | – | – | Jun 15, 2026 |
| Pramod Gupta | EVP, Pharmaceuticals and BD | 41,845 | 0.15% | Jun 15, 2026 |
| Douglas Jermasek | EVP, Corporate Strategy | 175,012 | 0.63% | Jun 15, 2026 |
| Sara Kenkare-Mitra | Director | – | – | Jul 28, 2026 |
| Sandeep Laumas | Director | 105,815 | 0.38% | Jul 28, 2026 |
| Gaurav Aggarwal | Director | 1,789,915 | 6.43% | Aug 26, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Gaurav Aggarwal Director | Aug 25, 2025 | Conversion | +652,900 | – | – | 1,789,915 |
| Gaurav Aggarwal Director | Feb 18, 2025 | Conversion | +1,400,000 | – | – | 11,370,152 |
| Gaurav Aggarwal Director | Oct 9, 2024 | Conversion | +5,500,000 | – | – | 9,970,152 |
| Gaurav Aggarwal Director | Jul 11, 2023 | Conversion | +3,470,152 | – | – | 3,470,152 |
| Pramod Gupta EVP, Pharmaceuticals and BD | Jul 11, 2023 | Option exercise | +41,845 | – | – | 41,845 |
| Douglas Jermasek EVP of Corporate Strategy | Jul 11, 2023 | Option exercise | +104,612 | – | – | 175,012 |
| Shalabh K. Gupta CEO, Director | Jul 11, 2023 | Option exercise | +104,612 | – | – | 2,527,449 |
| Brigitte Schiller Director | Jul 15, 2022 | Option exercise | +26,738 | – | – | 26,738 |
| Brigitte Schiller Director | May 16, 2022 | Buy | +15,000 | $0.83 | $12.45K | 15,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Vivo Opportunity Fund Holdings, L.P. Director | Jul 1, 2026 | 1,789,916 | $9.45M | Jun 30, 2026 | PIPE |